General MedicationsINTRAVENOUSGeneric
CARMUSTINE
CARMUSTINE
Standard Dose
300MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview CARMUSTINE is listed in Drugs@FDA under application 215000 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CARMUSTINE Form and strength POWDER;INTRAVENOUS - 300MG/VIAL Sponsor ACCORD HLTHCARE Submission history Latest submission status date: 2022-05-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview CARMUSTINE is listed in Drugs@FDA under application 215000 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CARMUSTINE Form and strength POWDER;INTRAVENOUS - 300MG/VIAL Sponsor ACCORD HLTHCARE Submission history Latest submission status date: 2022-05-16 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.